tetano
Editor, Senior Moderator
Front Immunol
. 2026 Oct 22:17:1911139.
doi: 10.3389/fimmu.2026.1911139. eCollection 2026.
Wen-Chien Wang # 1 , Weiping Cao # 2 , Amrita Kumar 2 , Wadzanai P Mboko 2 , Ram Kamal 2 , Ekramy E Sayedahmed 1 , Suresh K Mittal 1
Affiliations Expand
Introduction: The rapid antigenic drift of influenza A hemagglutinin (HA) limits the effectiveness of current HA-focused vaccines. To address this challenge, we evaluated recombinant human (HAd) and bovine (BAd) adenoviral vectors expressing neuraminidase (NA) as an alternative strategy to elicit broad and protective mucosal immunity.
Methods: BALB/c mice were immunized intranasally with HAd- or BAd-based vectors expressing N9 NA. Antigen-specific cellular and humoral immune responses were quantified locally and systemically. Immunized mice were subsequently monitored for survival and protective efficacy following lethal homosubtypic or heterosubtypic (Group 1 [H1N1] and Group 2 [H3N2]) influenza A viral challenges.
Results: Intranasal immunization with both vectors induced strong systemic IgG and mucosal IgA responses, as well as robust systemic and local T-cell activation, providing complete protection against lethal homosubtypic challenge. Notably, the BAd-N9NA vector elicited stronger mucosal and cellular responses than the HAd-based counterpart. Regarding cross-protection, N9-based vaccination conferred partial protection against the Group 2 (H3N2) virus but failed against the Group 1 (H1N1) virus.
Discussion: These findings demonstrate that NA-expressing adenoviral vectors induce potent mucosal and cellular immunity that mediates strong homosubtypic protection. While conserved structural epitopes exist across N1, N2, and N9 subtypes, heterosubtypic protection is limited and remains constrained by phylogenetic group lineages and sequence conservation. Furthermore, these results highlight the BAd platform as a highly potent delivery system for maximizing NA-specific immunogenicity, offering valuable insights for the design of broadly protective NA-based vaccines.
Keywords: T cell immune response; bovine adenoviral vector; homosubtypic protection; human adenoviral vector; innate lymphoid cells (ILC); neuraminidase (NA); non-human adenoviral vector.
. 2026 Oct 22:17:1911139.
doi: 10.3389/fimmu.2026.1911139. eCollection 2026.
Intranasal adenoviral neuraminidase vaccine induces local and systemic immunity and homosubtypic protection against influenza A viruses
Wen-Chien Wang # 1 , Weiping Cao # 2 , Amrita Kumar 2 , Wadzanai P Mboko 2 , Ram Kamal 2 , Ekramy E Sayedahmed 1 , Suresh K Mittal 1
Affiliations Expand
- PMID: 42991109
- PMCID: PMC13736095
- DOI: 10.3389/fimmu.2026.1911139
Abstract
Introduction: The rapid antigenic drift of influenza A hemagglutinin (HA) limits the effectiveness of current HA-focused vaccines. To address this challenge, we evaluated recombinant human (HAd) and bovine (BAd) adenoviral vectors expressing neuraminidase (NA) as an alternative strategy to elicit broad and protective mucosal immunity.
Methods: BALB/c mice were immunized intranasally with HAd- or BAd-based vectors expressing N9 NA. Antigen-specific cellular and humoral immune responses were quantified locally and systemically. Immunized mice were subsequently monitored for survival and protective efficacy following lethal homosubtypic or heterosubtypic (Group 1 [H1N1] and Group 2 [H3N2]) influenza A viral challenges.
Results: Intranasal immunization with both vectors induced strong systemic IgG and mucosal IgA responses, as well as robust systemic and local T-cell activation, providing complete protection against lethal homosubtypic challenge. Notably, the BAd-N9NA vector elicited stronger mucosal and cellular responses than the HAd-based counterpart. Regarding cross-protection, N9-based vaccination conferred partial protection against the Group 2 (H3N2) virus but failed against the Group 1 (H1N1) virus.
Discussion: These findings demonstrate that NA-expressing adenoviral vectors induce potent mucosal and cellular immunity that mediates strong homosubtypic protection. While conserved structural epitopes exist across N1, N2, and N9 subtypes, heterosubtypic protection is limited and remains constrained by phylogenetic group lineages and sequence conservation. Furthermore, these results highlight the BAd platform as a highly potent delivery system for maximizing NA-specific immunogenicity, offering valuable insights for the design of broadly protective NA-based vaccines.
Keywords: T cell immune response; bovine adenoviral vector; homosubtypic protection; human adenoviral vector; innate lymphoid cells (ILC); neuraminidase (NA); non-human adenoviral vector.